Krystal Biotech, Inc. (NASDAQ:KRYS) Short Interest Down 8.9% in December

Krystal Biotech, Inc. (NASDAQ:KRYS) was the target of a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 3,370,000 shares, a decrease of 8.9% from the December 15th total of 3,700,000 shares. Based on an average daily trading volume, of 247,300 shares, the short-interest ratio is currently 13.6 days.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock opened at $148.39 on Friday. Krystal Biotech has a 1-year low of $107.50 and a 1-year high of $219.34. The company has a market capitalization of $4.27 billion, a PE ratio of 83.84 and a beta of 0.85. The business has a 50-day moving average of $170.98 and a 200-day moving average of $182.12.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm had revenue of $83.84 million during the quarter, compared to analyst estimates of $82.94 million. During the same quarter last year, the firm earned ($0.67) EPS. Krystal Biotech’s quarterly revenue was up 879.9% on a year-over-year basis. On average, equities analysts expect that Krystal Biotech will post 3.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Citigroup raised their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. HC Wainwright reissued a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research report on Wednesday, December 18th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $212.00 target price on shares of Krystal Biotech in a research report on Wednesday, December 18th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $206.67.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the sale, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 14.10% of the company’s stock.

Institutional Trading of Krystal Biotech

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wilmington Savings Fund Society FSB acquired a new position in Krystal Biotech during the 3rd quarter worth $40,000. Values First Advisors Inc. acquired a new position in Krystal Biotech in the third quarter worth about $53,000. GAMMA Investing LLC increased its holdings in Krystal Biotech by 184.8% in the third quarter. GAMMA Investing LLC now owns 430 shares of the company’s stock valued at $78,000 after buying an additional 279 shares during the last quarter. Huntington National Bank raised its stake in Krystal Biotech by 97.6% during the third quarter. Huntington National Bank now owns 573 shares of the company’s stock valued at $104,000 after buying an additional 283 shares in the last quarter. Finally, Blue Trust Inc. raised its stake in Krystal Biotech by 242.4% during the third quarter. Blue Trust Inc. now owns 582 shares of the company’s stock valued at $107,000 after buying an additional 412 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).